@article{28550, keywords = {Treatment Outcome, Trachoma, Pregnancy, Male, Infant, Humans, Female, Ethiopia, Drug Administration Schedule, Child, Preschool, Azithromycin, Anti-Bacterial Agents}, author = {Lakew T and House J and Hong KC and Yi E and Alemayehu W and Melese M and Zhou Z and Ray K and Chin S and Romero E and Keenan JD and Whitcher J and Gaynor B and Lietman TM}, title = {Reduction and return of infectious trachoma in severely affected communities in Ethiopia.}, abstract = {
BACKGROUND: Antibiotics are a major tool in the WHO's trachoma control program. Even a single mass distribution reduces the prevalence of the ocular chlamydia that causes trachoma. Unfortunately, infection returns after a single treatment, at least in severely affected areas. Here, we test whether additional scheduled treatments further reduce infection, and whether infection returns after distributions are discontinued.
METHODS: Sixteen communities in Ethiopia were randomly selected. Ocular chlamydial infection in 1- to 5-year-old children was monitored over four biannual azithromycin distributions and for 24 months after the last treatment.
FINDINGS: The average prevalence of infection in 1- to 5-year-old children was reduced from 63.5% pre-treatment to 11.5% six months after the first distribution (P<0.0001). It further decreased to 2.6% six months after the fourth and final treatment (P = 0.0004). In the next 18 months, infection returned to 25.2%, a significant increase from six months after the last treatment (P = 0.008), but still far lower than baseline (P<0.0001). Although the prevalence of infection in any particular village fluctuated, the mean prevalence of the 16 villages steadily decreased with each treatment and steadily returned after treatments were discontinued.
CONCLUSION: In some of the most severely affected communities ever studied, we demonstrate that repeated mass oral azithromycin distributions progressively reduce ocular chlamydial infection in a community, as long as these distributions are given frequently enough and at a high enough coverage. However, infection returns into the communities after the last treatment. Sustainable changes or complete local elimination of infection will be necessary.
TRIAL REGISTRATION: ClinicalTrials.gov NCT00221364.
}, year = {2009}, journal = {PLoS neglected tropical diseases}, volume = {3}, pages = {e376}, issn = {1935-2735}, url = {http://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0000376&type=printable}, doi = {10.1371/journal.pntd.0000376}, language = {eng}, }